Prothena Corp (PRTA)

$9.82 +0.07 (0.72%)
Market Cap 524.84M
Revenue (ttm) 135.16M
Net Income (ttm) -122.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.49%
Debt to Equity Ratio 0.00
Volume 362,600
Avg Vol 801,590
Day's Range N/A - N/A
Shares Out 53.83M
Stochastic %K 16%
Beta -0.11
Analysts Sell
Price Target $13.00

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antib...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 236 2500
Fax: 353 1 902 3510
Address:
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland
AIIAAIIA_88
AIIAAIIA_88 Oct. 17 at 8:47 PM
$PRTA All options related fuckery to kill the monthly $10 calls. They will buy back next week. Assholes. LMAO
0 · Reply
takingstock73
takingstock73 Oct. 15 at 3:52 PM
$PRTA some life
0 · Reply
takingstock73
takingstock73 Oct. 7 at 3:19 PM
$PRTA nice movement back over 10 on a red day
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Oct. 2 at 12:06 PM
$PRTA BMY needs to pay a significant loyalty ($BILLIONS) to PRTA upon success of its AD drug. Similarly, Roche needs to oay a significant loyalty ($BILLIONS) to PRTA upon success of its PD drug. Are you kidding me? This stock is only at 2 times the current cash level?? Just saying. 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
1 · Reply
Vavavoom
Vavavoom Oct. 2 at 12:36 AM
$PRTA fasttrack for AD …nice Where will this be in a week ?
1 · Reply
jheer
jheer Oct. 1 at 9:41 PM
$PRTA The U.S. FDA has granted Fast Track designation to Bristol Myers Squibb's (NYSE:BMY) BMS-986446, an anti-microtubule binding region-tau (anti-MTBR-tau) antibody in phase 2 for early Alzheimer's disease. The drugmaker said that in preclinical models, the asset led to major reductions in tau uptake and spread, as well as protection against behavioral deficits. "By neutralizing the spread and promoting the clearance of pathological tau, BMS-986446 aims to modify the underlying course of the disease with the ultimate goal of slowing or delaying disease progression," Bristol said in a news release. Bristol is partnered with Prothena (PRTA) on BMS-986446.
0 · Reply
CalculatedSwing
CalculatedSwing Oct. 1 at 4:02 PM
$BIVI 🚀 $BIVI heating up ahead of Oct 8 investor webinar—analysts flash Strong Buy with $16 PT from $1.90! Neuro pipeline crushing it on Alzheimer's & Parkinson's breakthroughs. Newbies, this is prime time to go all in for massive gains! 🌕 Tagging the neuro squad: $SAVA $ANVS $INMB $PRTA #Biotech #Neuro #AllIn
0 · Reply
Winning_calls
Winning_calls Oct. 1 at 1:48 PM
$PRTA u should join the team
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 29 at 10:58 PM
$PRTA The global Alzheimer's disease diagnostics market is projected to reach USD 25.53 billion by 2034 from USD 8.95 billion in 2024. The Parkinson's disease therapeutics market reached USD 5.92 billion in 2024 and is projected to grow at a CAGR of about 8.1% to USD 12.83 billion by 2033. Just saying.
0 · Reply
ravi077
ravi077 Sep. 29 at 7:57 PM
$PRTA consistent buying for last 1week.
0 · Reply
Latest News on PRTA
Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Oct 1, 2025, 4:45 PM EDT - 24 days ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 28, 2025, 4:05 PM EDT - 2 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 27, 2025, 4:05 PM EDT - 2 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 6, 2025, 9:00 AM EDT - 2 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 4, 2025, 4:05 PM EDT - 2 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jul 28, 2025, 4:05 PM EDT - 3 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Announces Corporate Restructuring

Jun 18, 2025, 4:05 PM EDT - 4 months ago

Prothena Announces Corporate Restructuring

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Jun 16, 2025, 1:06 AM EDT - 4 months ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Why Is Prothena Stock Trading Lower On Tuesday?

May 27, 2025, 7:43 AM EDT - 5 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025, 4:05 PM EDT - 5 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 9, 2025, 7:16 AM EDT - 6 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 6 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

May 1, 2025, 4:05 PM EDT - 6 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 8:45 PM EST - 8 months ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 20, 2025, 4:05 PM EST - 8 months ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 17, 2025, 6:10 PM EST - 8 months ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Feb 13, 2025, 4:05 PM EST - 9 months ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Prothena Announces Board of Directors Update

Dec 30, 2024, 4:05 PM EST - 10 months ago

Prothena Announces Board of Directors Update

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Dec 19, 2024, 1:05 AM EST - 11 months ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena to Report Third Quarter 2024 Financial Results on November 12

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Announces Leadership Team Updates

Sep 27, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Leadership Team Updates

Prothena to Participate in Upcoming Healthcare Conferences

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Report Second Quarter 2024 Financial Results on August 8

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena to Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Mar 4, 2024, 4:05 PM EST - 1 year ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23, 2024, 12:31 PM EST - 1 year ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 21, 2024, 4:05 PM EST - 1 year ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 11:53 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Feb 8, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Jan 8, 2024, 8:30 AM EST - 1 year ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena prepares for potential sale - Bloomberg News

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Sep 21, 2023, 1:39 PM EDT - 2 years ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 27, 2023, 7:23 AM EDT - 2 years ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Jul 10, 2023, 4:10 PM EDT - 2 years ago

Prothena Announces Bristol Myers Squibb Opt-in for Worldwide Rights of PRX005, a Novel Anti-MTBR-Tau Antibody

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Jun 27, 2023, 4:05 PM EDT - 2 years ago

Prothena Announces Phase 3 VITAL Clinical Trial Results Published in Blood Showing Survival Benefit in Patients with Mayo Stage IV AL Amyloidosis Treated with Birtamimab

Prothena to Participate in Jefferies 2023 Healthcare Conference

Jun 2, 2023, 4:05 PM EDT - 2 years ago

Prothena to Participate in Jefferies 2023 Healthcare Conference

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

May 16, 2023, 4:05 PM EDT - 2 years ago

Prothena Announces Appointment of Billy Dunn, M.D., to its Board of Directors

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

May 7, 2023, 2:28 AM EDT - 2 years ago

Prothena Biosciences' Unique Approach To Protein Misfolding Could Be The Future

AIIAAIIA_88
AIIAAIIA_88 Oct. 17 at 8:47 PM
$PRTA All options related fuckery to kill the monthly $10 calls. They will buy back next week. Assholes. LMAO
0 · Reply
takingstock73
takingstock73 Oct. 15 at 3:52 PM
$PRTA some life
0 · Reply
takingstock73
takingstock73 Oct. 7 at 3:19 PM
$PRTA nice movement back over 10 on a red day
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Oct. 2 at 12:06 PM
$PRTA BMY needs to pay a significant loyalty ($BILLIONS) to PRTA upon success of its AD drug. Similarly, Roche needs to oay a significant loyalty ($BILLIONS) to PRTA upon success of its PD drug. Are you kidding me? This stock is only at 2 times the current cash level?? Just saying. 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
1 · Reply
Vavavoom
Vavavoom Oct. 2 at 12:36 AM
$PRTA fasttrack for AD …nice Where will this be in a week ?
1 · Reply
jheer
jheer Oct. 1 at 9:41 PM
$PRTA The U.S. FDA has granted Fast Track designation to Bristol Myers Squibb's (NYSE:BMY) BMS-986446, an anti-microtubule binding region-tau (anti-MTBR-tau) antibody in phase 2 for early Alzheimer's disease. The drugmaker said that in preclinical models, the asset led to major reductions in tau uptake and spread, as well as protection against behavioral deficits. "By neutralizing the spread and promoting the clearance of pathological tau, BMS-986446 aims to modify the underlying course of the disease with the ultimate goal of slowing or delaying disease progression," Bristol said in a news release. Bristol is partnered with Prothena (PRTA) on BMS-986446.
0 · Reply
CalculatedSwing
CalculatedSwing Oct. 1 at 4:02 PM
$BIVI 🚀 $BIVI heating up ahead of Oct 8 investor webinar—analysts flash Strong Buy with $16 PT from $1.90! Neuro pipeline crushing it on Alzheimer's & Parkinson's breakthroughs. Newbies, this is prime time to go all in for massive gains! 🌕 Tagging the neuro squad: $SAVA $ANVS $INMB $PRTA #Biotech #Neuro #AllIn
0 · Reply
Winning_calls
Winning_calls Oct. 1 at 1:48 PM
$PRTA u should join the team
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 29 at 10:58 PM
$PRTA The global Alzheimer's disease diagnostics market is projected to reach USD 25.53 billion by 2034 from USD 8.95 billion in 2024. The Parkinson's disease therapeutics market reached USD 5.92 billion in 2024 and is projected to grow at a CAGR of about 8.1% to USD 12.83 billion by 2033. Just saying.
0 · Reply
ravi077
ravi077 Sep. 29 at 7:57 PM
$PRTA consistent buying for last 1week.
0 · Reply
Winning_calls
Winning_calls Sep. 29 at 12:37 PM
$PRTA join us
0 · Reply
Winning_calls
Winning_calls Sep. 29 at 3:05 AM
$PRTA pick me up @ $9.40
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 25 at 11:27 PM
$PRTA Idiot bears who kept on saying “CMO resigned” is a bad sign. But they do not understand that the company wants to sell to the highest bidder once all its PD and AD drug candidate concepts are proven. It will be hovering about $10 for some time then will be sold for $2B + ($40 per share), IMHO. I have been saying this for 9 momths now. What is PD and AD market worth? Everyone is getting old and about 1/4 will develop the horrible diseases. 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥
1 · Reply
sepsis74
sepsis74 Sep. 24 at 8:04 PM
$PRTA what's going on? Is RFK Jr. getting fired?
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 24 at 7:58 PM
$PRTA Prelude to a minimum 300% ($40/share) UP day soon! JMO 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
1 · Reply
Newtimmy
Newtimmy Sep. 24 at 7:12 PM
$PRTA Somebody is on steady buy the whole damn day
0 · Reply
takingstock73
takingstock73 Sep. 24 at 7:08 PM
$PRTA nice
0 · Reply
resistancebreakers
resistancebreakers Sep. 24 at 6:54 PM
$PRTA 🕵️‍♂️🪖🫡
0 · Reply
Newtimmy
Newtimmy Sep. 22 at 6:33 AM
$PRTA Good week to knock $9 down
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Sep. 17 at 4:34 PM
$PRTA No volume for two days. Sellers all sold out?
0 · Reply
buyandsold
buyandsold Sep. 17 at 2:35 PM
$PRTA this sits where it does because they are sitting on cash they dont need and there is a fear they will set it alight on a new science project
0 · Reply
takingstock73
takingstock73 Sep. 12 at 2:29 AM
$PRTA
0 · Reply